News | May 24, 2024
Swixx Biopharma acquires Biopas to expand in Latin America
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The project funding will be done through a mix of internal accruals and debts.
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
